Omeprazole
- Generic Name
- Omeprazole
- Brand Names
- Konvomep, Losec, Omeclamox, Omesec, Previdolrx Analgesic Pak, Prilosec, Talicia, Yosprala, Zegerid, Zegerid Reformulated Aug 2006, Zegerid With Magnesium Hydroxide
- Drug Type
- Small Molecule
- Chemical Formula
- C17H19N3O3S
- CAS Number
- 73590-58-6
- Unique Ingredient Identifier
- KG60484QX9
- Background
Originally approved by the FDA in 1989, omeprazole is a proton-pump inhibitor, used to treat gastric acid-related disorders. These disorders may include gastroesophageal reflux disease (GERD), peptic ulcer disease, and other diseases characterized by the oversecretion of gastric acid. This drug was the first clinical useful drug in its class, and its approva...
- Indication
Omeprazole, according to the FDA label is a proton pump inhibitor (PPI) used for the following purposes:
• Treatment of active duodenal ulcer in adults
• Eradication of Helicobacter pylori to reduce the risk of duodenal ulcer
recurrence in adults
• Treatment of active benign gastric ulcer in adults
...
- Associated Conditions
- Ankylosing Spondylitis (AS), Duodenal Ulcer, Erosive Esophagitis, Gastric Ulcer, Gastro-esophageal Reflux Disease (GERD), Healing, Heartburn, Helicobacter Pylori Infection, Osteoarthritis (OA), Rheumatoid Arthritis, Upper GI Bleeding, Zollinger-Ellison Syndrome, Benign, active Gastric Ulcer, Develop NSAID-induced gastric ulcers, Hypersecretory conditions, Multiple endocrine adenomas
- Associated Therapies
- -
A Single-Dose Study to Investigate the Pharmacokinetics of MK-7655 in Participants With Impaired Renal Function (MK-7655-005)
- Conditions
- Interventions
- First Posted Date
- 2011-01-12
- Last Posted Date
- 2020-06-11
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 49
- Registration Number
- NCT01275170
Comparing Omeprazole With Fluoxetine for Treatment of Non Erosive Reflux Disease and Its Subgroups: a Double-blind Placebo-controlled Clinical Trial
- Conditions
- Interventions
- First Posted Date
- 2011-01-04
- Last Posted Date
- 2012-03-06
- Lead Sponsor
- Tehran University of Medical Sciences
- Target Recruit Count
- 144
- Registration Number
- NCT01269788
- Locations
- 🇮🇷
Gasterointestinal endoscopy ward, Amir Alam hospital, Tehran university of medical sciences, Tehran, Iran, Islamic Republic of
Impact of Omeprazole and Fluvoxamine on Platelet Response to Clopidogrel
- Conditions
- Interventions
- First Posted Date
- 2011-01-04
- Last Posted Date
- 2015-08-19
- Lead Sponsor
- Hadassah Medical Organization
- Target Recruit Count
- 15
- Registration Number
- NCT01269333
- Locations
- 🇮🇱
Hadassah Medical Organization, Jerusalem, Israel
Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced Solid Tumors
- First Posted Date
- 2010-10-11
- Last Posted Date
- 2014-12-23
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 17
- Registration Number
- NCT01218620
- Locations
- 🇺🇸
University of Wisconsin Hospital and Clinics, Madison, Wisconsin, United States
Omeprazole Delayed Release (DR) Capsules Bioequivalence Study of Dr. Reddys Under Fed Condition
- First Posted Date
- 2010-07-27
- Last Posted Date
- 2010-07-27
- Lead Sponsor
- Dr. Reddy's Laboratories Limited
- Target Recruit Count
- 54
- Registration Number
- NCT01170182
Omeprazole Delayed Release (DR) Capsules Bioequivalence Study of Dr. Reddys Under Fasting Conditions
- First Posted Date
- 2010-07-27
- Last Posted Date
- 2010-07-27
- Lead Sponsor
- Dr. Reddy's Laboratories Limited
- Target Recruit Count
- 44
- Registration Number
- NCT01170169
Study to Assess the Pharmacodynamics/Pharmacokinetics After Repeated Dosing of D961H 10 mg and Omeprazole 10 mg in Japanese Healthy Male Subjects
- First Posted Date
- 2010-07-09
- Last Posted Date
- 2010-09-21
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 42
- Registration Number
- NCT01159145
- Locations
- 🇯🇵
Research Site, Tokyo, Japan
Mucosta in Gastric Ulcer Treatment, Effectiveness and Safety Evaluation
- First Posted Date
- 2010-06-24
- Last Posted Date
- 2013-02-04
- Lead Sponsor
- Otsuka Pakistan Limited
- Target Recruit Count
- 129
- Registration Number
- NCT01150162
- Locations
- 🇵🇰
Dr. Ziauddin University Hospital, Karachi, Pakistan
🇵🇰Dow University of Health Sciences, Karachi, Pakistan
🇵🇰Abbasi Shaheed Hospital, Karachi, Pakistan
Study Evaluating Effect of Esomeprazole, Omeprazole or Lansoprazole on the Pharmacodynamics (PD) and Pharmacokinetics (PK) of Clopidogrel
- Conditions
- Interventions
- First Posted Date
- 2010-06-22
- Last Posted Date
- 2011-06-28
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 149
- Registration Number
- NCT01147588
- Locations
- 🇺🇸
Research Site, Overland Park, Kansas, United States
Comparison of Antisecretory Effect of a Single Dose of Rabeprazole 20 mg and Omeprazole 20 mg in Obese Subjects
- Conditions
- Interventions
- First Posted Date
- 2010-06-03
- Last Posted Date
- 2010-09-24
- Lead Sponsor
- Nantes University Hospital
- Registration Number
- NCT01136317
- Locations
- 🇫🇷
CHU de Nantes, Nantes, France
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.